
Press Release

(North Brunswick, New Jersey) 3D Biotek, LLC, a biotech company engaged in the development of 3-dimensional cell culture (3D) devices and technologies, announced today that they had launched a new product, 3D Insert™ –PS, for general 3-dimensional cell culture application. The company is expecting that this 3D Insert™ –PS will have a wide application in drug toxicity screening, drug target screening, stem cell expansion, and tissue engineering fields.

“Compare to conventional 2-dimensional (2D) cell culture, 3D cell culture offers a better cell culture environment because it is one step closer to in vivo cellular environment”, said Mr. Wing Lau, the Chief Operating Officer at 3D Biotek. “Current cell cultures are being conducted in traditional 2D cell culture vessels, that is, cells are being cultured in monolayer in cell culture plates and flasks. It is well known that cells in human body live and grow in a 3D environment. Therefore, most leading researchers agreed that 3D cell culture will be the future cell culture technology. However, because 2D cell culture is easy to carry out and there are no easy-to-use and convenient 3D cell culture devices available, 2D cell culture is still the predominant cell culture technique”. Mr. Lau continued, “the launch of 3D Insert™ –PS is a significant step towards the transition of 2D to 3D cell culture, because our 3D Insert™ –PS is very easy and convenient to use. We have received very positive feedback from our customers who tested our products, so we are very confident that the use of our 3D Insert™ –PS will enable our customers getting more accurate in vitro results, accelerating their product development speed and reducing their overall product development cost”.

“We would like to take this opportunity to express our gratitude to the financial support from NJ Commission on Science and Technology (NJCST). We would not be able to release our new product so quickly without the support of both NJ incubator seed funding and NJ technology fellowship funding from NJCST. With the help of these two grants, we will be able to continue our pipeline product development”, Mr. Lau added. He also announced, “ Today, we are very happy to announce that two scientific abstracts regarding the use of our 3D cell culture products, namely 3D Insert™ –PCL and 3D Insert™ –PS, have been accepted by the 2008 Annual Meeting of American Society for Cell Biology which will be held in San Francisco, CA. from Dec 13 -17, 2008. Two posters will be exhibited during the conference. We’ll also have an exhibition booth in the conference to showcase our products and technology”.

About 3D Biotek, LLC: Headquartered in North Brunswick, New Jersey, 3D Biotek is engaged in the commercialization of novel 3-dimensional cell culture devices for stem cell/tissue engineering research and drug discovery applications. The first product line that 3D Biotek intends to market is 3D Insert™, which is a series of novel 3-dimensional (3D) porous scaffolds for conducting 3D cell culture in stem cell, tissue engineering, and in vitro drug candidate screening. The company had launched its first product, 3D Insert™ - PCL in April 2008, and will launch 3D Insert™ – PS in November 2008.

For more information on 3D Biotek’s products and technologies, please visit the company’s website at <http://www.3dbiotek.com> or contact Mr. Wing Lau by phone, mail or email (wlau@3dbiotek.com).